StockData

KALA BIO, Inc. (KALA) stock

KALANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026Score 5/30
$3.43−0.40 (-10.44%)

Close on Nov 17, 2026Market cap $66.34MP/E –Yield –

Kala Bio r&d expenses

Research and development expenses are spending on new products and technology.

Kala Bio's R&D Expenses for the twelve months ending Jun 30, 2026 was $6.61M, down 70.9% year over year. For fiscal 2025 it was $18.78M, down 15.0% from the year before. Over ten years it grew 5.1% a year on average. The highest annual figure on record is $29.29M in fiscal 2018.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$18.78M-15.0%
FY2024Dec 31, 2024$22.09M+18.9%
FY2023Dec 31, 2023$18.59M+5.3%
FY2022Dec 31, 2022$17.65M+53.3%
FY2021Dec 31, 2021$11.52M-37.3%
FY2020Dec 31, 2020$18.35M-32.7%
FY2019Dec 31, 2019$27.28M-6.9%
FY2018Dec 31, 2018$29.29M+1.0%
FY2017Dec 31, 2017$29.01M+15.9%
FY2016Dec 31, 2016$25.03M+119.9%
FY2015Dec 31, 2015$11.38M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$59.00K-99.1%
Q1 FY2026Mar 31, 2026$61.00K-99.0%
Q4 FY2025Dec 31, 2025$366.00K-93.0%
Q3 FY2025Sep 30, 2025$6.13M+18.6%
Q2 FY2025Jun 30, 2025$6.23M+17.2%
Q1 FY2025Mar 31, 2025$6.06M-4.7%
Q4 FY2024Dec 31, 2024$5.26M+11.4%
Q3 FY2024Sep 30, 2024$5.17M-6.9%
Q2 FY2024Jun 30, 2024$5.32M+24.3%
Q1 FY2024Mar 31, 2024$6.35M+57.4%
Q4 FY2023Dec 31, 2023$4.72M+42.0%
Q3 FY2023Sep 30, 2023$5.55M+3.0%
Q2 FY2023Jun 30, 2023$4.28M-4.4%
Q1 FY2023Mar 31, 2023$4.04M-9.6%
Q4 FY2022Dec 31, 2022$3.32M+37.7%
Q3 FY2022Sep 30, 2022$5.39M+87.1%
Q2 FY2022Jun 30, 2022$4.47M+44.6%
Q1 FY2022Mar 31, 2022$4.47M+42.9%
Q4 FY2021Dec 31, 2021$2.41M-28.9%
Q3 FY2021Sep 30, 2021$2.88M-16.9%
Q2 FY2021Jun 30, 2021$3.09M-48.9%
Q1 FY2021Mar 31, 2021$3.13M-42.5%
Q4 FY2020Dec 31, 2020$3.40M-44.7%
Q3 FY2020Sep 30, 2020$3.47M-50.9%
Q2 FY2020Jun 30, 2020$6.05M-14.8%
Q1 FY2020Mar 31, 2020$5.43M-21.9%
Q4 FY2019Dec 31, 2019$6.14M-33.6%
Q3 FY2019Sep 30, 2019$7.07M+0.6%
Q2 FY2019Jun 30, 2019$7.11M-3.5%
Q1 FY2019Mar 31, 2019$6.96M+23.0%
Q4 FY2018Dec 31, 2018$9.24M+57.1%
Q3 FY2018Sep 30, 2018$7.03M+0.1%
Q2 FY2018Jun 30, 2018$7.37M-8.7%
Q1 FY2018Mar 31, 2018$5.66M-29.6%
Q4 FY2017Dec 31, 2017$5.88M-14.9%
Q3 FY2017Sep 30, 2017$7.02M-15.0%
Q2 FY2017Jun 30, 2017$8.07M–
Q1 FY2017Mar 31, 2017$8.04M–
Q4 FY2016Dec 31, 2016$6.91M–
Q3 FY2016Sep 30, 2016$8.26M–

More Kala Bio figures

See a number that looks wrong?